Navigation Links
Surveyed Physicians Will Treat Over 50 Percent of Hepatitis C Genotype 1-Infected Patients With the Protease Inhibitor Telaprevir
Date:8/4/2009

he protease inhibitors on their formularies. Of these pharmacy directors, 10 percent expect to choose telaprevir while 30 percent say that they do not have a preference regarding telaprevir or boceprevir based on clinical data provided to them but will use cost as the basis for their selection.

Hepatitis C: Impact of and Receptivity to Novel Antivirals Among Payers and Prescribers is based on a U.S. survey of 84 gastroenterologists, 16 hepatologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled On the Verge of a Paradigm Shift in the Hepatitis C Virus Market: Physician and Payer Perceptions of Telaprevir, Boceprevir and Other Key Novel Antivirals. This webinar will be held on Thursday, September 3, 2009 at 10 a.m. U.S. Eastern Time. For more information, contact Christopher Comfort at 781-296-2597.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more informa
'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved
2. For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibbs Orencia
3. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
4. For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
5. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
6. Surveyed Psychiatrists and PCPs Expect to Increase Their First-Line Use of SNRIs Over the Next Two Years for the Treatment of Generalized Anxiety Disorder
7. For Alzheimers Disease, Surveyed Neurologists Identify a Therapys Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
8. For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms
9. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
10. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
11. For Atrial Fibrillation, Surveyed Experts Indicate That Multaq, Celivarone and ATI-2042 Have Advantages Over Propafenone in the Maintenance of Normal Sinus Rhythm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... The report “Polycarbonate Resin Market by ... 2018” defines and segments the global polycarbonate resin ... revenue and consumption. It also identifies driving and ... with analysis of trends, opportunities, burning issues, winning ... revenues are forecasted on the basis of major ...
(Date:8/23/2014)... 2014 Having been in the dental field ... Arlington, Texas, saw a need for an effective way to ... I came up with the idea for my design," she ... way for a user to clean the mouth without a ... items. It also helps avoid plaque buildup and maintains proper ...
(Date:8/23/2014)... CA (PRWEB) August 23, 2014 ... trading system created by Greg Marks has been generating ... earlier this month. The commotion surrounding the new product ... an investigative review. , “In recent years ... trading software systems, commonly referred to as robots or ...
(Date:8/23/2014)... Boston, MA (PRWEB) August 23, 2014 ... now have a study aid in preparing for Food ... safety practice test by Dynamic Path. , Dynamic ... study module, which includes more than 200 review questions ... study materials are designed to cover requirements of the ...
(Date:8/23/2014)... August 23, 2014 Youth substance abuse ... It’s no different in Houston, TX. Substance abuse can ... victim to drug and alcohol dependency in higher numbers ... to beat substance abuse, but don’t know where to ... facility can be a challenge because most treatment options ...
Breaking Medicine News(10 mins):Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... better prognosis, study finds , , FRIDAY, Dec. 12 (HealthDay News) ... the risk of getting breast cancer, but women who take ... risk of dying from the disease, a new study suggests. ... particular type of cancer that is easier to treat," explained ...
... Ariz., Dec. 12 Roberta Kalafut, D.O., just announced her ... to a close the worst abuses of power by the ... unjust disciplinary actions, particularly against her competitors, and stonewalling by ... , "We applaud Kalafut,s resignation," said AAPS Executive ...
... Fair Offers New Chemists and Chemical Engineers an Opportunity to ... , PRINCETON, N.J., Dec. 12 Informex ... the upcoming InformexUSA exhibition in San Francisco free of charge. ... 25 and under to learn more about the chemical technologies ...
... saw disease stabilize or improve, study shows , , ... combination of medicines designed to boost immune function ... interim results from an ongoing Mayo Clinic study. ... immunomodulatory drug called pomalidomide with dexamethasone (pom/dex) improved ...
... At its 12th annual holiday gala The,Teddy Bear ... Award to Steve,Mosko, President of Sony Pictures Television ... to children with special needs. Grammy(R),winning singer-songwriter Kenny ... of the Heart. Long standing friend and colleague ...
... YORK, Dec. 12 In his last public remarks as,the ... Lilly and Company (NYSE: LLY ), today said ... markets and regulatory environments,encourage and reward companies for the long-term, ... bench to the bedside. , ...
Cached Medicine News:Health News:HRT Users Who Get Breast Cancer Less Likely to Die 2Health News:HRT Users Who Get Breast Cancer Less Likely to Die 3Health News:AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next 2Health News:Informex Invites Young Chemists to Attend InformexUSA 2Health News:Informex Invites Young Chemists to Attend InformexUSA 3Health News:Combo Therapy Helps Multiple Myeloma Patients 2Health News:The Help Group's Teddy Bear Ball Salutes Sony Pictures Television President, Steve Mosko and Features Performance by Kenny Loggins 2Health News:Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies 2Health News:Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies 3
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... 21, 2014 Nektar Therapeutics (NASDAQ: ... announced positive results from its Phase 3 pivotal ... half-life recombinant factor VIII (rFVIII) treatment for hemophilia ... met its primary endpoint in reducing annualized bleed ... the on-demand arm. Top-line results from ...
(Date:8/21/2014)... 2014 /CNW/ - Eisai Limited is pleased to support the ... comic book available in Canada . The ... to educate children and their parents about epilepsy, the most ... more than 300,000 Canadians. Eisai is guided by a corporate ... which the patient is central – there was a need ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... 22, 2011     ... catch up   with   their urban counterparts in adopting technology ...   data spill shows risk of online health records . ... IT and its current challenges? Ambitious national healthcare IT programmes and ...
... Aug. 20, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: ... leading China-based biotechnology company focused on researching, developing, ... the annual general meeting of shareholders of 3SBio ... at 10:00 a.m., Shenyang time, at our executive ...
Cached Medicine Technology:Innovations in E-Health & Informatics Europe: The Need for a European EHealth Strategy 23SBio Inc. to Hold 2011 Annual General Meeting on September 20, 2011 2
Right angled 5 mm blunt hook. Overall length: 9.9 inches....
Fine short working end. Overall length: 4.9 inches. Most popular size or model....
11.5 mm curved hook. Flat serrated handle with polished finish. Overall length: 5.9 inches....
Designed for manipulating one piece lenses. The "Y: hook is excellent for capturing haptics and centering the lens. Straight shaft with "Y" shaped tip. Round knurled handle with dull finish. Overall ...
Medicine Products: